SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon trades in fine fettle amidst sluggish trade

23 Jul 2012 Evaluate

Biocon is currently trading at Rs 246.00, up by 0.85 points or 0.35% from its previous closing of Rs 245.15 on the BSE.

The scrip opened at Rs 243.00 and has touched a high and low of Rs 246.70 and Rs 242.05 respectively. So far 14311 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 373.60 on 26-Jul-2011 and a 52 week low of Rs 208.10 on 04-Jun-2012.

Last one week high and low of the scrip stood at Rs 253.50 and Rs 243.70 respectively. The current market cap of the company is Rs 4925.00 crore.

The promoters holding in the company stood at 60.91% while Institutions and Non-Institutions held 14.30% and 24.78% respectively.

Biocon, a Bangalore-based Pharma company is looking for merger of its wholly-owned subsidiary Biocon Biopharmaceuticals with itself. The company will take the final decision on July 25 in a meeting of the Board of Directors of the company, a day before the company’s Annual General Meeting.

Biocon Biopharmaceuticals was established as a joint venture with a Cuban partner in 2003 to provide manufacturing support for biopharmaceuticals, and then became a wholly-owned subsidiary of Biocon in April 2010.

Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

358.20 7.65 (2.18%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×